This single-center cohort study assesses the association of tumor mutational burden status in patients with metastatic castration-resistant prostate cancer and response to immune checkpoint inhibitor therapy.
JAMA oncology. 2024 Feb 08 [Epub ahead of print]
Peter D Zang, Neal S Chawla, Regina Barragan-Carrillo, Alex Chehrazi-Raffle, Abhishek Tripathi, Sumanta K Pal, Tanya B Dorff
Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, California.